

Published on 06 Oct 2025 by

**Henry Wendisch**

Equity Research

henry.wendisch@nuways-ag.com

Guidance raised again and CMD hosted; chg. set & PT raised

Last week, we not only hosted TPG at our **European MidCap Event in Paris**, but TPG also raised its mid-term guidance again following recent acquisitions and hosted a CMD. Here are our key takeaways:

Pharma acquisitions signed: TPG entered agreements to acquire a 50% +1 stake in (1) Pharmosan Group, Austria, (2) Vamida Versandapotheke, Czech Republic and (3) Apothekia, Germany. All three companies are expected to generate sales of € 130m in FY'26e with an EBITDA margin of 7-8% (in line with TPG's margin targets). Closing is expected at end of FY'25e, thus a full year effect is only expected for FY'26e. The strategic rationale behind the acquisitions is the filling of an important gap in the B2B pharmacy value chain. To be precise, pharmacies rely on manifold B2B companies before being able to serve customers (online and offline). For example, ApoNow (acquired in 2021) already bridges the gap between pharma manufacturers and local (offline) pharmacies. Now TPG fills another open gap with the pharma distributor Pharmosan, the pharma-education platform Apothekia. Furthermore, TPG adds the Austrian online pharmacy Vamida to its portfolio, which can be used as a platform for TPG's existing pharma offering. **This makes TPG a key partner for pharmacies, being present along almost the entire value chain.** Acquisition prices were not disclosed, but we estimate a price of 3-5x EV/EBITDA on the back of past acquisition multiples, which implies a payment of € 15-25m for 50%+1 (eNuW). With that, the current segment "Service & Retail Goods" will be renamed to "Pharma & Service Goods".

FY'26e targets raised: Having signed the deals above, TPG raised its FY'26e mid-term targets to € >1bn (prev.: € > 860m) and € 70-80m adj. EBITDA (prev.: € >64m). The FY'25 guidance remains unchanged as the acquisitions will be closed at the end of the year and should thus not have an impact on FY'25 figures.

Optics & hearing identified as a highly profitable key growth market. Another key discussion point was the ongoing market entry into optics & hearing. The newly formed segment will contribute significantly to the group's profitability with EBITDA margins of around 25%. Moreover, the strategic rationale pays off well into TPG's platform strategy. TPG already announced two more acquisitions to follow in Q4'25e, however, given the demographic development of pharmacists (average age of 54 and 25% of store owners older than 60), many more acquisition opportunities with strong negotiation power should arise in the future.

With the recent acquisitions now reflected in our model, we increase our **DCF-based PT to € 21.00** (old: € 19.00) and reiterate our **BUY recommendation**.

Y/E 31.12. (EUR m)	2022	2023	2024	2025e	2026e	2027e
Sales	168.4	432.2	524.6	720.4	1,020.2	1,114.1
Sales growth	-30.0%	156.6%	21.4%	37.3%	41.6%	9.2%
EBITDA	14.1	46.8	55.6	71.0	96.1	107.0
Net debt (if net cash=0)	11.5	60.0	87.1	140.4	106.9	40.7
FCF	1.7	97.1	49.9	21.7	33.5	66.2
Net Debt/EBITDA	0.8	1.3	1.6	2.0	1.1	0.4
EPS reported	0.39	1.48	1.60	2.11	3.02	3.40
EBITDA margin	8.4%	10.8%	10.6%	9.9%	9.4%	9.6%
ROCE	6.5%	25.5%	19.5%	18.7%	20.9%	22.3%
EV/sales	0.8	0.4	0.5	0.5	0.3	0.2
EV/EBITDA	6.1	3.6	4.4	4.6	3.0	2.1
PER	11.1	4.2	5.0	4.3	3.0	2.7
Adjusted FCF yield	1.9%	58.5%	20.6%	6.6%	11.4%	29.2%

Source: Company Data, NuWays AG | e = estimate, p = preliminary

Close Price as of 03.10.2025

BUY 

old: Buy

Target

EUR 21.00

old: EUR 19.00

Upside

130.8%

Share Performance



High/low 52 weeks (EUR)	12.7 / 7.1
3m rel. performance	-3.81%
6m rel. performance	8.33%
12m rel. performance	16.07%

Market Data

Share Price (in €)	9.10
Market Cap (in € m)	185.79
Number of Shares (in m pcs)	20.42
Enterprise Value (in € m)	326.20
Ø Volume (6 Months, in k)	257

Ticker

Bloomberg	TPG GR
WKN	A2QEFA
ISIN	DE000A2QEFA1

Key Shareholders

Benner Holding GmbH	69.80%
Free Float	21.20%
Paladin Asset Management	9.00%

Guidance

FY'25 ('26) GMV: € 1.3bn (€ 1.7bn)
 FY'25 ('26) sales: € 715-735m (€ >1bn)
 FY'25 ('26) adj. EBITDA: € 54-58m (7-8% margin)

Forecast Changes

	2025e	2026e	2027e
Sales	-	17%	17%
EBITDA	-	7%	5%
EPS	-	6%	3%


Comment on changes

Recent acquisitions are now incorporated in our model.

Company Profile

The Platform Group is a leading software specialist enabling eCommerce for small and medium sized partners. It operates online platforms across ~25 verticals, serving B2C (e.g. fashion, home & living) and B2B markets (e.g. industrial machines, dental equipment) in DACH. Its proprietary software allows to quickly connect new partners / platforms and TPG takes care of the platform integration, putting the dealers' products live on more than 50 channels including Zalando, amazon and eBay.

Segment Breakdown



Catalysts

- Potential M&A activities could yield upside to our estimates

Investment Case

- Scalable e-commerce platform built on proprietary, hard-to-replicate software, serving a diverse and growing base of small businesses and partners. Growth is driven by an expanding product offering that enhances platform value through network effects.
- TPG shows strong margins even relative to larger competitors, despite intense competition from major online retailers across all sectors.
- Low CAPEX and working capital requirements via the pure platform approach.

Upcoming Events

Nov 14	Publication of Q3 Report
--------	--------------------------

SWOT Analysis

Strengths

- Multi-sector platform with strong growth through add-ons of various verticals.
- High reach & economies of scale with 15k partner retailers and international presence via many sales channels
- End-to-end e-commerce service, enabling partners to go online quickly and without their own expertise

Weaknesses

- Dependence on consumer sentiment.
- Strong competition in many e-commerce verticals.

Opportunities

- Platform approach as an enabler for partner to go online
- Cost synergies through centralized platform software approach

Threats

- Post-acquisition integration risks
- Risk of overleveraging and rising interest payments potentially burdening cashflows

Financials

Profit and loss (EUR m)	2022	2023	2024	2025e	2026e	2027e
Net sales	168.4	432.2	524.6	720.4	1,020.2	1,114.1
Sales growth	-30.0%	156.6%	21.4%	37.3%	41.6%	9.2%
Increase/decrease in finished goods and work-in-process	0.0	0.0	0.0	0.0	0.0	0.0
Total sales	168.4	432.2	524.6	720.4	1,020.2	1,114.1
Other operating income	3.5	32.0	29.1	16.6	10.2	11.1
Material expenses	123.8	318.5	355.7	475.5	672.7	733.8
Personnel expenses	11.3	21.6	28.3	45.0	56.7	60.7
Other operating expenses	22.7	77.4	114.1	145.5	205.0	223.7
Total operating expenses	154.3	385.4	469.0	649.4	924.2	1,007.1
EBITDA	14.1	46.8	55.6	71.0	96.1	107.0
Depreciation	5.0	7.8	9.8	10.5	14.7	15.9
EBITA	9.1	38.9	45.8	60.5	81.3	91.1
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	9.1	38.9	45.8	60.5	81.3	91.1
Interest income	0.4	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.7	6.4	9.5	13.3	13.3	13.3
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	-0.3	-6.4	-9.4	-13.3	-13.3	-13.3
Recurring pretax income from continuing operations	8.8	32.5	36.3	47.2	68.1	77.8
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	8.8	32.5	36.3	47.2	68.1	77.8
Income tax expense	0.8	-0.4	0.8	1.9	3.4	5.1
Net income from continuing operations	8.0	32.9	35.5	45.3	64.7	72.7
Income from discontinued operations (net of tax)	0.0	6.4	2.8	0.0	0.0	0.0
Net income	8.0	26.5	32.7	45.3	64.7	72.7
Minority interest	1.3	0.9	1.6	2.2	3.1	3.4
Net profit (reported)	6.7	31.9	33.9	43.2	61.6	69.4
Average number of shares	17.3	17.3	19.5	20.4	20.4	20.4
EPS reported	0.39	1.48	1.60	2.11	3.02	3.40

Source: Company Data, NuWays AG

Profit and loss (common size)	2022	2023	2024	2025e	2026e	2027e
Net sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales growth	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Increase/decrease in finished goods and work-in-process	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Total sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Other operating income	2.1%	7.4%	5.6%	2.3%	1.0%	1.0%
Material expenses	73.5%	73.7%	67.8%	66.0%	65.9%	65.9%
Personnel expenses	6.7%	5.0%	5.4%	6.2%	5.6%	5.5%
Other operating expenses	13.5%	17.9%	21.8%	20.2%	20.1%	20.1%
Total operating expenses	91.6%	89.2%	89.4%	90.1%	90.6%	90.4%
EBITDA	8.4%	10.8%	10.6%	9.9%	9.4%	9.6%
Depreciation	3.0%	1.8%	1.9%	1.5%	1.4%	1.4%
EBITA	5.4%	9.0%	8.7%	8.4%	8.0%	8.2%
Amortisation of goodwill	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Amortisation of intangible assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Impairment charges	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT (inc revaluation net)	5.4%	9.0%	8.7%	8.4%	8.0%	8.2%
Interest income	0.3%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest expenses	0.4%	1.5%	1.8%	1.8%	1.3%	1.2%
Investment income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Financial result	-0.2%	-1.5%	-1.8%	-1.8%	-1.3%	-1.2%
Recurring pretax income from continuing operations	5.2%	7.5%	6.9%	6.6%	6.7%	7.0%
Extraordinary income/loss	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings before taxes	5.2%	7.5%	6.9%	6.6%	6.7%	7.0%
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income from continuing operations	4.7%	7.6%	6.8%	6.3%	6.3%	6.5%
Income from discontinued operations (net of tax)	0.0%	1.5%	0.5%	0.0%	0.0%	0.0%
Net income	4.7%	6.1%	6.2%	6.3%	6.3%	6.5%
Minority interest	0.8%	0.2%	0.3%	0.3%	0.3%	0.3%
Net profit (reported)	4.0%	5.9%	5.9%	6.0%	6.0%	6.2%

Source: Company Data, NuWays AG

Balance sheet (EUR m)	2022	2023	2024	2025e	2026e	2027e
Intangible assets	30.3	107.8	136.7	211.7	211.7	211.7
Property, plant and equipment	9.6	9.7	18.0	15.5	10.8	9.9
Financial assets	15.3	0.0	4.6	4.6	4.6	4.6
Fixed Assets	55.3	117.5	159.3	231.8	227.1	226.1
Inventories	13.4	92.3	73.3	100.7	142.6	155.7
Accounts receivable	6.3	41.2	33.2	45.5	63.8	69.0
Other assets and short-term financial assets	5.0	18.1	30.1	30.1	30.1	30.1
Liquid assets	4.2	7.6	22.1	13.8	47.3	113.5
Deferred taxes	0.0	3.0	5.2	5.2	5.2	5.2
Deferred charges and prepaid expenses	0.0	4.6	0.0	0.0	0.0	0.0
Current Assets	28.9	166.8	163.9	195.3	289.0	373.5
Total Assets	84.2	284.3	323.2	427.1	516.0	599.6
Shareholders Equity	45.4	80.5	131.9	175.0	236.6	306.0
Minority interest	1.8	1.1	3.2	5.4	8.5	11.9
Long-term liabilities to banks	11.8	32.3	33.1	68.1	68.1	68.1
Bonds (long-term)	0.0	0.0	50.0	60.0	60.0	60.0
other interest-bearing liabilities	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0
Other provisions and accrued liabilities	1.9	3.0	2.7	2.7	2.7	2.7
NON-CURRENT LIABILITIES	13.7	35.3	85.8	130.8	130.8	130.8
Short-term liabilities to banks	4.0	35.3	26.1	26.1	26.1	26.1
Accounts payable	4.1	41.1	36.3	49.9	74.1	85.0
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0
Accrued taxes	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities (incl. from lease and rental contracts)	13.7	76.9	30.4	30.4	30.4	30.4
Deferred taxes	1.6	14.0	9.5	9.5	9.5	9.5
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
Current Liabilities	23.3	167.3	102.3	115.9	140.2	151.0
Total Liabilities and Shareholders Equity	84.2	284.3	323.2	427.1	516.0	599.6

Source: Company Data, NuWays AG

Balance sheet (common size)	2022	2023	2024	2025e	2026e	2027e
Intangible assets	36.0%	37.9%	42.3%	49.6%	41.0%	35.3%
Property, plant and equipment	11.4%	3.4%	5.6%	3.6%	2.1%	1.7%
Financial assets	18.2%	0.0%	1.4%	1.1%	0.9%	0.8%
Fixed Assets	65.6%	41.3%	49.3%	54.3%	44.0%	37.7%
Inventories	15.9%	32.5%	22.7%	23.6%	27.6%	26.0%
Accounts receivable	7.5%	14.5%	10.3%	10.7%	12.4%	11.5%
Other assets and short-term financial assets	6.0%	6.4%	9.3%	7.0%	5.8%	5.0%
Liquid assets	5.0%	2.7%	6.9%	3.2%	9.2%	18.9%
Deferred taxes	0.0%	1.1%	1.6%	1.2%	1.0%	0.9%
Deferred charges and prepaid expenses	0.0%	1.6%	0.0%	0.0%	0.0%	0.0%
Current Assets	34.4%	58.7%	50.7%	45.7%	56.0%	62.3%
Total Assets	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Shareholders Equity	53.9%	28.3%	40.8%	41.0%	45.9%	51.0%
Minority interest	2.1%	0.4%	1.0%	1.3%	1.6%	2.0%
Long-term liabilities to banks	14.0%	11.4%	10.2%	15.9%	13.2%	11.4%
Bonds (long-term)	0.0%	0.0%	15.5%	14.0%	11.6%	10.0%
other interest-bearing liabilities	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Provisions for pensions and similar obligations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other provisions and accrued liabilities	2.3%	1.1%	0.8%	0.6%	0.5%	0.4%
NON-CURRENT LIABILITIES	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Short-term liabilities to banks	4.7%	12.4%	8.1%	6.1%	5.1%	4.4%
Accounts payable	4.9%	14.4%	11.2%	11.7%	14.4%	14.2%
Advance payments received on orders	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accrued taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other liabilities (incl. from lease and rental contracts)	16.2%	27.1%	9.4%	7.1%	5.9%	5.1%
Deferred taxes	1.9%	4.9%	2.9%	2.2%	1.8%	1.6%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current Liabilities	27.7%	58.9%	31.7%	27.1%	27.2%	25.2%
Total Liabilities and Shareholders Equity	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company Data, NuWays AG

Cash flow (EUR m)	2022	2023	2024	2025e	2026e	2027e
Net profit/loss	6.7	26.5	32.7	45.3	64.7	72.7
Depreciation of fixed assets (incl. leases)	5.0	7.8	9.8	10.5	14.7	15.9
Amortisation of goodwill & intangible assets	0.0	0.0	0.0	0.0	0.0	0.0
Other costs affecting income / expenses	0.0	-12.8	-6.9	0.0	0.0	0.0
Cash flow from operating activities	0.7	96.3	48.1	19.2	28.8	65.3
Increase/decrease in inventory	0.0	10.0	19.0	-27.4	-41.9	-13.1
Increase/decrease in accounts receivable	0.0	8.7	8.0	-12.4	-18.3	-5.2
Increase/decrease in accounts payable	0.0	11.8	-4.7	13.5	24.3	10.9
Increase/decrease in other working capital positions	0.0	51.5	0.0	0.0	0.0	0.0
Increase/decrease in working capital	0.0	82.0	22.3	-26.2	-35.9	-7.4
Cash flow from operating activities	5.7	104.1	58.0	29.7	43.5	81.2
CAPEX	4.0	7.0	8.1	8.0	10.0	15.0
Payments for acquisitions	0.0	58.8	48.4	75.0	0.0	0.0
Financial investments	0.0	9.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	-4.0	-74.8	-56.5	-83.0	-10.0	-15.0
Cash flow before financing	1.7	29.3	1.5	-53.3	33.5	66.2
Increase/decrease in debt position	-5.0	-21.9	22.1	45.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	-4.0	-9.1	0.0	0.0	0.0
Effects of exchange rate changes on cash	0.0	-0.0	0.0	0.0	0.0	0.0
Cash flow from financing activities	-5.0	-25.9	13.1	45.0	0.0	0.0
Increase/decrease in liquid assets	-3.4	3.4	14.5	-8.3	33.5	66.2
Liquid assets at end of period	4.2	7.6	22.1	13.8	47.3	113.5

Source: Company Data, NuWays AG

Key ratios	2022	2023	2024	2025e	2026e	2027e
P&L growth analysis						
Sales growth	-30.0%	156.6%	21.4%	37.3%	41.6%	9.2%
EBITDA growth	91.3%	231.4%	19.0%	27.6%	35.3%	11.4%
EBIT growth	305.0%	326.7%	17.7%	32.1%	34.5%	11.9%
EPS growth	30.5%	282.1%	8.3%	32.0%	42.7%	12.6%
Efficiency						
Sales per employee	0.0	0.0	1,151.8	906.2	927.5	910.2
EBITDA per employee	0.0	0.0	122.1	89.3	87.3	87.4
No. employees (average)	0	0	456	795	1,100	1,224
Balance sheet analysis						
Avg. working capital / sales	9.3%	15.9%	8.2%	13.1%	9.9%	10.6%
Inventory turnover (sales/inventory)	29.0	78.0	51.0	51.0	51.0	51.0
Accounts receivable turnover	13.6	34.8	23.1	23.1	22.8	22.6
Accounts payable turnover	8.9	34.7	25.3	25.3	26.5	27.8
Cash flow analysis						
Free cash flow	1.7	97.1	49.9	21.7	33.5	66.2
Free cash flow/sales	1.0%	22.5%	9.5%	3.0%	3.3%	5.9%
FCF / net profit	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Capex / sales	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Solvency						
Net debt	11.5	60.0	87.1	140.4	106.9	40.7
Net Debt/EBITDA	0.8	1.3	1.6	2.0	1.1	0.4
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest paid / avg. debt	4.7%	11.7%	15.1%	12.0%	10.1%	8.6%
Returns						
ROCE	6.5%	25.5%	19.5%	18.7%	20.9%	22.3%
ROE	14.7%	31.7%	23.6%	24.7%	26.0%	22.7%
Adjusted FCF yield	1.9%	58.5%	20.6%	6.6%	11.4%	29.2%
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
DPS	0.0	0.0	0.0	0.0	0.0	0.0
EPS reported	0.39	1.48	1.60	2.11	3.02	3.40
Average number of shares	17.3	17.3	19.5	20.4	20.4	20.4
Valuation ratios						
P/BV	1.6	1.3	1.2	1.1	0.8	0.6
EV/sales	0.8	0.4	0.5	0.5	0.3	0.2
EV/EBITDA	6.1	3.6	4.4	4.6	3.0	2.1
EV/EBIT	9.4	4.3	5.3	5.4	3.6	2.5

Source: Company Data, NuWays AG

Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of Conflict of Interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

1. or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
2. or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company
3. or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
4. The analysed company holds 5% or more of the share capital of NuWays AG
5. holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
6. or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
7. or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
8. The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
The Platform Group AG	2

Historical target price and rating changes for The Platform Group AG

Company	Date	Analyst	Rating	Target Price	Close
The Platform Group AG	29.08.2025	Henry Wendisch	Buy	EUR 19.00	EUR 9.70
	29.07.2025	Henry Wendisch	Buy	EUR 18.00	EUR 8.90

1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months.

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness

6. Competent Supervisory Authority

NuWays AG is registered at the BaFin - the Federal Financial Supervisory Authority, Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 - 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 06/10/2025 08:00 AM

Date of publication dissemination: 06/10/2025 08:00 AM

Contact

NuWays AG

Mittelweg 16-17
20148 Hamburg
Germany

+49 170 119 8648
info@nuways-ag.com
www.nuways-ag.com



Christian Sandherr

Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com

Find us on Social Media

Instagram



LinkedIn



X



YouTube

